{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-021411","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2022-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.263805+00:00","generated_at":"2026-06-26T05:13:41.086123+00:00","sec_items":["2.02","7.01","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nektar announces strategic reorganization, 70% workforce reduction, cash runway to H1 2025","bullets":["Workforce reduced by ~70%; expects charge of $150-160M in Q2 2022.","Cash runway extended into first half of 2025; Q1 2022 cash & investments ~$704M.","CMO Dr. Dimitry Nuyten stepping down; Dr. Brian Kotzin to succeed.","CCO John Northcott to depart June 2022; remains as strategic advisor through 2022.","Preliminary Q1 revenue ~$25M; R&D expense ~$110M; gain of ~$33M from SFJ derivative."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-021411","json":"https://secwatch.observer/filing/0001213900-22-021411.json","markdown":"https://secwatch.observer/filing/0001213900-22-021411.md","text":"https://secwatch.observer/filing/0001213900-22-021411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390022021411/0001213900-22-021411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390022021411/ea158792-8k_nektarthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:13:41.086123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48cc400337","claim":"John Northcott departed as Senior Vice President and Chief Commercial Officer at NEKTAR THERAPEUTICS.","evidence_excerpt":"John Northcott will step down as Senior Vice President and Chief Commercial Officer of the Company in June 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390022021411/0001213900-22-021411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}